List of Excipients in Branded Drug BUPIVACAINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing BUPIVACAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	bupivacaine hydrochloride	0143-9328	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	bupivacaine hydrochloride	0143-9328	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	bupivacaine hydrochloride	0143-9328	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in BUPIVACAINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS DEXTROSE
2	DEXTROSE
35	HYDROCHLORIC ACID

Bupivacaine Hydrochloride Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 25, 2026

Bupivacaine hydrochloride is a mature local anesthetic with broad generic availability and limited composition-of-matter protection. Commercial opportunity is concentrated in differentiated formulations, preservative-free presentations, ready-to-use delivery systems, extended-release products, and manufacturing improvements. The core injectable drug has low regulatory and patent barriers, but clinical adoption depends on concentration, route, sterility assurance, packaging, dosing convenience, and compatibility with regional anesthesia workflows.

What is bupivacaine hydrochloride used for?

Bupivacaine hydrochloride is an amide-type local anesthetic used for local infiltration, peripheral nerve block, epidural anesthesia, and caudal anesthesia. Approved concentrations commonly include 0.25%, 0.5%, and 0.75%, although availability varies by product and jurisdiction. The drug is supplied as a sterile aqueous solution, typically adjusted to an acidic pH to maintain solubility and chemical stability.

Commercial products include:

Product type	Typical concentration	Common excipient strategy	Primary use
Bupivacaine HCl injection	0.25%	Sodium chloride, water for injection, pH adjustment	Infiltration and nerve block
Bupivacaine HCl injection	0.5%	Sodium chloride, water for injection, pH adjustment	Nerve block and epidural use
Bupivacaine HCl injection	0.75%	Sodium chloride, water for injection, pH adjustment	Selected epidural and surgical anesthesia
Bupivacaine HCl with dextrose	Often 0.75%	Dextrose, sodium chloride or other tonicity adjustment, water	Spinal anesthesia
Bupivacaine HCl with epinephrine	0.25% or 0.5%	Epinephrine, antioxidant or pH-control system, sodium chloride	Longer local effect and reduced systemic absorption
Liposomal bupivacaine	1.3%	Multivesicular lipid system, sucrose, phospholipids, cholesterol, triglycerides	Extended-release infiltration analgesia

The last product, liposomal bupivacaine, is commercially distinct from conventional bupivacaine hydrochloride. Exparel contains bupivacaine in a multivesicular liposome system and is not a conventional bupivacaine HCl solution.[1]

What excipients are used in bupivacaine hydrochloride injections?

The excipient platform for conventional bupivacaine HCl is intentionally narrow. The formulation normally uses an aqueous vehicle, sodium chloride for isotonicity, and pH adjustment with hydrochloric acid or sodium hydroxide. Some products contain preservatives, while single-dose and neuraxial presentations are generally designed to be preservative-free.

Core excipient functions

Excipient or component	Function	Commercial relevance
Water for injection	Solvent and injectable vehicle	Universal requirement
Sodium chloride	Tonicity adjustment	Supports injection comfort and physiologic compatibility
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls solubility and product stability
Dextrose	Hyperbaric spinal formulation and density control	Enables intrathecal product differentiation
Epinephrine	Pharmacologic adjunct	Extends local effect and acts as a vasoconstrictor
Sodium metabisulfite or related antioxidant	Protects epinephrine-containing formulations	Raises sensitivity and labeling considerations
Preservatives such as methylparaben	Multidose container preservation	Generally unsuitable for neuraxial use
Phospholipids and cholesterol	Extended-release carrier system	Relevant to liposomal, not conventional HCl products

The principal excipient decision is not the addition of complex functional ingredients. It is the selection of a formulation that satisfies sterility, tonicity, pH, container compatibility, preservative restrictions, and route-specific requirements.

Which excipient strategies offer the strongest commercial opportunity?

The strongest opportunities are in route-specific and workflow-specific formulations rather than simple reformulation of standard bupivacaine HCl.

1. Preservative-free unit-dose presentations

Preservative-free bupivacaine HCl in ready-to-use vials, ampoules, prefilled syringes, and regional anesthesia kits has a clear hospital-use rationale. Neuraxial administration places strict limits on preservatives and particulate contamination. A supplier can differentiate through:

• Low-fill-volume unit doses
• Color-coded labels by concentration
• Luer-lock prefilled syringes
• Barcoded packaging for medication administration systems
• Terminally sterilized presentations where feasible
• Reduced overfill and waste
• Compatibility with automated anesthesia carts

The active ingredient is commoditized, but packaging and supply reliability can support hospital contracts.

2. Hyperbaric spinal formulations

Hyperbaric bupivacaine HCl uses dextrose to increase solution density relative to cerebrospinal fluid. Density influences intrathecal spread and block characteristics. This creates an excipient-led product distinction without changing the active pharmaceutical ingredient.

The main development issues are:

• Density consistency across the shelf life
• Osmolality control
• Syringe and ampoule compatibility
• Control of particulate matter
• Accurate labeling of baricity
• Preservation-free status for intrathecal administration

A manufacturer with validated density control and reliable single-dose packaging can compete in spinal anesthesia even when conventional bupivacaine products are widely available.

3. Epinephrine-containing products

Bupivacaine HCl with epinephrine combines local anesthesia with vasoconstriction. The formulation must control epinephrine oxidation, pH drift, oxygen exposure, and light sensitivity. Antioxidants may be required, but those excipients create additional labeling and tolerability considerations.

Commercial differentiation can come from:

• Longer labeled shelf life
• Low-sorption container systems
• Light-protective packaging
• Reduced headspace oxygen
• Stable prefilled syringes
• Clear separation of concentrations and epinephrine strengths

Epinephrine-containing products also face a more complex stability program than plain bupivacaine HCl.

4. Ready-to-administer surgical presentations

A ready-to-use bupivacaine HCl product can reduce preparation time and medication errors. The commercial value is strongest in ambulatory surgery centers, emergency departments, dental surgery, labor and delivery, and regional anesthesia services.

Potential product formats include:

• 10 mL and 20 mL prefilled syringes
• Large-volume bags for epidural infusion
• Procedure-specific kits
• Dual-compartment systems
• Concentration-specific packaging
• Combination kits containing needles, filters, or administration accessories

The accessory components may be protected through device patents or design rights even when the drug formulation is not patentable.

What patents protect bupivacaine hydrochloride products?

Conventional bupivacaine HCl has limited patent protection because the active ingredient and basic aqueous injection technology are old. Generic products generally compete under abbreviated new drug application pathways, subject to product-specific FDA requirements.

Patent value is more likely to arise from:

• Extended-release delivery systems
• Liposomal or polymeric encapsulation
• Combination products
• Specific dosing regimens
• Surgical procedure claims
• Device-enabled delivery
• Manufacturing methods
• Container and packaging systems
• Stability improvements
• Drug admixture compatibility

Exparel illustrates the commercial value of formulation patents. Pacira’s product uses a multivesicular liposome platform and has been associated with patents covering liposomal bupivacaine compositions and administration methods.[2] These patents protect a delivery system rather than the basic bupivacaine molecule.

What is the Orange Book status of bupivacaine hydrochloride?

The FDA Orange Book includes multiple bupivacaine hydrochloride injection products and related dosage forms. The relevant patents and exclusivities must be reviewed by reference product, strength, route, and formulation because listings differ across products.[3]

For conventional bupivacaine HCl:

• Composition-of-matter exclusivity is expired.
• Generic competition is established.
• Paragraph IV risk is generally concentrated in formulation, device, or method-of-use products.
• A standard injectable product usually faces more regulatory than patent risk.
• Product-specific Orange Book entries must be checked before relying on an expiration date.

For liposomal bupivacaine, patent and regulatory analysis is separate from conventional bupivacaine HCl. A generic applicant may need to address formulation, process, analytical characterization, and patent-listing issues associated with the complex liposomal system.

When does bupivacaine hydrochloride lose exclusivity?

Bupivacaine hydrochloride lost practical market exclusivity decades ago. The drug was approved in the United States in the 1970s, and conventional generic injection products have long been marketed.[4] No current commercial strategy should assume protection from the active ingredient itself.

Exclusivity risk should instead be assessed by product category:

Product category	Exclusivity position	Primary barrier
Plain bupivacaine HCl injection	Generic market	Manufacturing quality and supply
Preservative-free single-dose injection	Generally generic	Sterility, packaging, route suitability
Hyperbaric spinal bupivacaine	Generic or abbreviated pathway	Density, sterility, labeling
Bupivacaine with epinephrine	Generic competition	Stability and combination-product controls
Liposomal bupivacaine	Higher formulation barrier	Complex delivery system and patent estate
Bupivacaine device combination	Product-specific	Device, human factors, and combination-product requirements

Which companies compete in bupivacaine hydrochloride?

The market includes large generic injectable manufacturers, specialty anesthesia suppliers, hospital-contract manufacturers, and branded extended-release developers. Major commercial participants have included Pfizer, Fresenius Kabi, Hikma, Eugia, Sagent Pharmaceuticals, and other generic manufacturers, depending on product, strength, and market.

Competition is based on:

• FDA-approved presentations
• Backorder performance
• Contract pricing
• National distribution
• Hospital formulary access
• Container format
• Preservative-free availability
• Shortage resilience
• Manufacturing redundancy

The FDA has repeatedly identified injectable drugs as vulnerable to supply disruption because of sterile manufacturing complexity and limited manufacturing capacity.[5] This creates an opportunity for suppliers that can maintain reliable production, even without meaningful patent protection.

What manufacturing and excipient barriers affect bupivacaine HCl?

The main barriers are operational rather than molecular.

Sterile manufacturing

Bupivacaine HCl injections require validated aseptic processing or terminal sterilization, depending on the formulation and container system. Critical controls include:

• Bioburden management
• Sterility assurance
• Endotoxin control
• Particulate limits
• Container-closure integrity
• Extractables and leachables
• Fill-volume accuracy
• In-process pH and osmolality

Container compatibility

The formulation must be evaluated against glass vials, polymer ampoules, plastic syringes, elastomeric closures, and infusion bags. Epinephrine-containing products create greater oxidation and adsorption concerns. Plastic systems may create permeability or sorption issues that are less significant in simple bupivacaine HCl solutions.

Preservative restrictions

A multidose product may use a preservative, but that approach is not suitable for every route. Neuraxial products require particularly conservative excipient selection. A company seeking broad route labeling may need separate preservative-free and multidose presentations.

Analytical development

Analytical methods must distinguish bupivacaine from degradation products and, for advanced delivery systems, quantify free versus encapsulated drug. Key assays include:

• Potency
• Related substances
• pH
• Osmolality
• Particulate matter
• Sterility and endotoxin
• Preservative content
• Container-closure integrity
• Release profile for extended-release systems

How does bupivacaine HCl compare with liposomal bupivacaine?

Attribute	Conventional bupivacaine HCl	Liposomal bupivacaine
Dosage form	Aqueous solution	Multivesicular liposome suspension
Excipient complexity	Low	High
Manufacturing difficulty	Moderate sterile injectable	High sterile complex injectable
Generic competition	Extensive	More limited
Patent exposure	Low for basic product	Higher formulation and method exposure
Onset and duration	Established short-to-intermediate profile	Extended-release profile
Cost position	Low	Premium
Key commercial advantage	Price and availability	Duration and reduced administration burden
Main development risk	Sterility and supply	Release control, particle structure, and bioequivalence

A conventional bupivacaine HCl product cannot generally claim the commercial profile of liposomal bupivacaine without demonstrating a materially differentiated delivery system. Simply adding a standard excipient is unlikely to create equivalent duration or defensible patent protection.

What generic launch risks exist for bupivacaine products?

For conventional bupivacaine HCl, generic launch risk is low from a patent perspective but can remain high from a commercial perspective. A new entrant must overcome:

• Price compression
• Established hospital contracts
• FDA manufacturing inspections
• Sterile injectable shortages
• Limited purchasing slots
• Need for multiple concentrations
• Pharmacovigilance and recall exposure
• Supply-chain requirements for raw materials and containers

For advanced formulations, the risk profile changes. A Paragraph IV challenge may be relevant where Orange Book-listed patents cover a branded extended-release product. The applicant must also address formulation equivalence, analytical similarity, release behavior, and potential device or administration-method claims.[3]

How can a company build a defensible bupivacaine excipient strategy?

The strongest strategy is a layered product architecture:

1. Develop a preservative-free core product in the most used concentrations.
2. Add hyperbaric and epinephrine-containing versions where the clinical channel supports them.
3. Use ready-to-administer packaging to reduce preparation and waste.
4. Protect the container, kit, manufacturing process, and stability package.
5. Reserve complex lipid or polymer delivery systems for premium products.
6. Generate compatibility data for common anesthetic devices and infusion systems.
7. Pursue hospital contracts based on supply reliability rather than molecule-level differentiation.
8. Build geographic redundancy for sterile fill-finish and critical excipients.

Licensing opportunities are more credible in delivery technology, prefilled syringe systems, liposomal platforms, and procedure-specific kits than in the bupivacaine molecule itself. A licensee should assess freedom to operate around carrier composition, release kinetics, surgical indications, and device integration before investing in clinical development.

Key Takeaways

• Conventional bupivacaine hydrochloride is a mature, generic injectable with no meaningful active-ingredient exclusivity.
• Excipient strategy is most valuable in preservative-free, hyperbaric, epinephrine-containing, and ready-to-use products.
• Dextrose creates a commercially relevant hyperbaric spinal formulation but does not create broad composition-of-matter protection.
• Liposomal bupivacaine is a separate, higher-value formulation category with greater manufacturing and patent barriers.
• The main competitive advantages in standard bupivacaine HCl are supply reliability, packaging, hospital workflow, and route-specific compliance.
• Patent opportunities are concentrated in delivery systems, manufacturing, devices, kits, and method-of-use claims.
• FDA regulatory and sterile-manufacturing execution are more important than molecule-level patent protection for conventional products.

FAQs

Is bupivacaine hydrochloride the same as liposomal bupivacaine?

No. Conventional bupivacaine hydrochloride is an aqueous solution. Liposomal bupivacaine uses a multivesicular lipid delivery system and has different formulation, manufacturing, labeling, and patent considerations.[1]

Can preservatives be used in bupivacaine hydrochloride injections?

Preservatives may be used in selected multidose products, but preservative-free formulations are generally preferred or required for neuraxial applications. The permitted excipient profile depends on route, presentation, labeling, and applicable FDA requirements.

Does adding dextrose create a new patentable bupivacaine product?

Usually not by itself. Dextrose can create a clinically differentiated hyperbaric formulation, but patentability would depend on the complete formulation, manufacturing method, use, or delivery system rather than the simple presence of dextrose.

What is the best commercial format for a new bupivacaine HCl product?

A preservative-free, ready-to-use, unit-dose syringe or vial with reliable supply and clear concentration differentiation is generally more commercially defensible than another standard multidose vial.

Are biosimilar rules relevant to bupivacaine hydrochloride?

No. Bupivacaine hydrochloride is a small-molecule drug, so conventional generic drug pathways apply. Biosimilar rules are relevant to biologics, not standard bupivacaine injections.

References

1. Pacira Pharmaceuticals, Inc. (2021). EXPAREL (bupivacaine liposome injectable suspension) prescribing information. U.S. Food and Drug Administration.

2. U.S. Patent and Trademark Office. (n.d.). Patent documents relating to liposomal bupivacaine formulations and methods of use. https://patents.google.com/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2019). Drug shortages: Root causes and potential solutions. U.S. Department of Health and Human Services.